Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Three-arm Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates in Healthy Adult Participants

NCT06632990 is registered in ClinicalTrials.gov with Allyx Therapeutics as lead sponsor.

NCT NCT06632990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06632990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Three-arm Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates in Healthy Adult Participants
Lead sponsor
Allyx Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 4, 2024
Completion date
October 15, 2025
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug drug interaction (ddi)